These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 36902392)
1. Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins. Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902392 [TBL] [Abstract][Full Text] [Related]
2. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Wang YF; Jiang CC; Kiejda KA; Gillespie S; Zhang XD; Hersey P Clin Cancer Res; 2007 Aug; 13(16):4934-42. PubMed ID: 17652623 [TBL] [Abstract][Full Text] [Related]
3. Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells. Bauer D; Werth F; Nguyen HA; Kiecker F; Eberle J Cell Death Dis; 2017 Feb; 8(2):e2594. PubMed ID: 28151482 [TBL] [Abstract][Full Text] [Related]
4. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429 [TBL] [Abstract][Full Text] [Related]
5. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686 [TBL] [Abstract][Full Text] [Related]
6. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853 [TBL] [Abstract][Full Text] [Related]
8. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849 [TBL] [Abstract][Full Text] [Related]
9. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression. Phadke MS; Sini P; Smalley KS Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592 [TBL] [Abstract][Full Text] [Related]
14. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900 [TBL] [Abstract][Full Text] [Related]
15. Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Jiang CC; Lucas K; Avery-Kiejda KA; Wade M; deBock CE; Thorne RF; Allen J; Hersey P; Zhang XD Cancer Res; 2008 Aug; 68(16):6708-17. PubMed ID: 18701495 [TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. Wong DJ; Robert L; Atefi MS; Lassen A; Avarappatt G; Cerniglia M; Avramis E; Tsoi J; Foulad D; Graeber TG; Comin-Anduix B; Samatar A; Lo RS; Ribas A Mol Cancer; 2014 Aug; 13():194. PubMed ID: 25142146 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells. Jane EP; Premkumar DR; Morales A; Foster KA; Pollack IF J Pharmacol Exp Ther; 2014 Jul; 350(1):22-35. PubMed ID: 24741074 [TBL] [Abstract][Full Text] [Related]
18. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1. Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174 [TBL] [Abstract][Full Text] [Related]
19. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656 [TBL] [Abstract][Full Text] [Related]
20. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]